New York, NY (PRWEB) March 20, 2006
Action to Cure Kidney Cancer (ACKC) awards $45,000 to Paul Cairns to purchase a real-time PCR (Polymerase Chain Reaction) system that will expedite his work in the development of a urine-screening test for early stage kidney cancer as well as his research in the monitoring of treatment for the disease. This technology will enable Dr. Cairns to identify one cancer cell in 10,000 normal cells, a tenfold increase in accuracy over previous technology.
Kidney cancer strikes more than 36,000 Americans each year, and over 12,500 succumb to the disease for which few treatment options are currently available.
Dr. Cairns is a pioneering researcher on the trail of genetic markers that identify kidney cancer. He joined Fox Chase in 1998 after a postdoctoral fellowship at Johns Hopkins. He was educated in the United Kingdom where he received his Ph.D. in clinical genetics at the University of Birmingham and completed his postdoctoral fellowship in the epithelial carcinogenesis at the Mari Curie Research Institute in Surrey.
ACKC is a grassroots organization established in 2003 by kidney cancer patients and their families/caregivers who are working to raise awareness of kidney cancer and to ensure that it receives the public and private funding required to identify and develop effective treatment modalities and to find a cure for this disease. ACKC works with government officials, research institutions, and other interested organizations and individuals to increase the level of funding for kidney cancer research.
Fox Chase Cancer Center was founded in 1904 in Philadelphia, Pa. as the nation's first cancer hospital. In 1974, Fox Chase became one of the first institutions designated as a National Cancer Institute Comprehensive Cancer Center.
# # #